184 related articles for article (PubMed ID: 27256157)
1. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
Tota JE; Ramanakumar AV; Villa LL; Richardson H; Burchell AN; Coutlée F; Franco EL
J Infect Dis; 2016 Sep; 214(5):676-84. PubMed ID: 27256157
[TBL] [Abstract][Full Text] [Related]
2. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
3. Exploring individual HPV coinfections is essential to predict HPV-vaccination impact on genotype distribution: a model-based approach.
Pons-Salort M; Letort V; Favre M; Heard I; Dervaux B; Opatowski L; Guillemot D
Vaccine; 2013 Feb; 31(8):1238-45. PubMed ID: 23246257
[TBL] [Abstract][Full Text] [Related]
4. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of carcinogenic human papillomavirus infection in Suzhou: Epidemiology, vaccine evaluation, and associated diseases.
Li WJ; Xu HX; Chen ZH; Xu WD; Wu YJ
J Med Virol; 2017 May; 89(5):895-901. PubMed ID: 27696465
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
8. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
9. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
Woestenberg PJ; King AJ; van Benthem BHB; Donken R; Leussink S; van der Klis FRM; de Melker HE; van der Sande MAB; Hoebe CJPA; Bogaards JA;
J Infect Dis; 2018 Jan; 217(2):213-222. PubMed ID: 29140439
[TBL] [Abstract][Full Text] [Related]
10. Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.
Dunne EF; Naleway A; Smith N; Crane B; Weinmann S; Braxton J; Steinau M; Unger ER; Markowitz LE
J Infect Dis; 2015 Dec; 212(12):1970-5. PubMed ID: 26123561
[TBL] [Abstract][Full Text] [Related]
11. Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study.
Orlando G; Fasolo M; Mazza F; Ricci E; Esposito S; Frati E; Zuccotti GV; Cetin I; Gramegna M; Rizzardini G; Tanzi E;
Hum Vaccin Immunother; 2014; 10(4):986-94. PubMed ID: 24423757
[TBL] [Abstract][Full Text] [Related]
12. Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012.
Berenson AB; Laz TH; Rahman M
J Infect Dis; 2016 Dec; 214(12):1961-1964. PubMed ID: 27821406
[TBL] [Abstract][Full Text] [Related]
13. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
[TBL] [Abstract][Full Text] [Related]
14. Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.
Tricco AC; Ng CH; Gilca V; Anonychuk A; Pham B; Berliner S
BMC Infect Dis; 2011 Sep; 11():235. PubMed ID: 21892939
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old).
Hirth JM; Chang M; Resto VA;
Vaccine; 2017 Jun; 35(27):3446-3451. PubMed ID: 28526331
[TBL] [Abstract][Full Text] [Related]
16. High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
Konopnicki D; Manigart Y; Gilles C; Barlow P; De Marchin J; Feoli F; Delforge M; Clumeck N; De Wit S
AIDS; 2016 Jan; 30(3):425-33. PubMed ID: 26765936
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination.
Tota JE; Jiang M; Ramanakumar AV; Walter SD; Kaufman JS; Coutlée F; Richardson H; Burchell AN; Koushik A; Mayrand MH; Villa LL; Franco EL
PLoS One; 2016; 11(12):e0166329. PubMed ID: 28005904
[TBL] [Abstract][Full Text] [Related]
18. An anal cancer screening program for MSM in Italy: Prevalence of multiple HPV types and vaccine-targeted infections.
Garbuglia AR; Gentile M; Del Nonno F; Lorenzini P; Lapa D; Lupi F; Pinnetti C; Baiocchini A; Libertone R; Cicalini S; Capobianchi MR; Ammassari A
J Clin Virol; 2015 Nov; 72():49-54. PubMed ID: 26397204
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
20. A Study of Human Papillomavirus Genotypes Specificity and the Vaccines Introducing System for Korean-Chinese Women in the Yanbian Autonomous Region.
Wu Q; Kuk JH; Ryu YJ
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3331-3338. PubMed ID: 33247692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
